PHA Sacubitril
(Die Seite wurde neu angelegt: „Published oct 29, 2021 sacubitril (entresta)inhibits trpm7 my personal target of interest. -essential papers- {{tp|p=C8565918|t=2021. Focus on pharmacogenom…“)
Zum nächsten Versionsunterschied →
Version vom 22. November 2021, 09:29 Uhr
Published oct 29, 2021 sacubitril (entresta)inhibits trpm7 my personal target of interest.
-essential papers-
C8565918 2021. Focus on pharmacogenomics phytonutrient-drug interactions and COVID-19 vaccines: Perspectives on ADRs ADEs and SEDs.
C8444447 2021. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.
C8317454 2021. Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2.
C7890335 2021. The spectrum of COVID-19 in complex adult congenital heart disease: A case series.
C8326513 2021. Receptors
C8091429 2021. PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19.
32921718 2020. How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.
31399990 2019. Antifibrotic Roles of RAAS Blockers: Update.
32502882 2020. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
33827074 2021. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
32639866 2020. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
32370986 2020. Renin-angiotensin-aldosterone system and COVID-19 infection.
34066998 2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.
34134920 2021. Vasoactive Peptides: Their Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.
32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
34715788 2021. Cardiogenic shock complicating multisystem inflammatory syndrome following COVID-19 infection: a case report.
33795925 2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.
32998363 2020. Angiotensin Inhibition, TGF-beta and EMT in Cancer.
32671601 2021. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
33926209 2021. CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia.
32537662 2020. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection.
34055238 2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.
33631357 2021. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.
33005549 2020. COVID-19 Presenting as Major Thromboembolic Events: Virchow's Triad Revisited and Clinical Considerations of Therapeutic Anticoagulation.
33200501 2021. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission.
32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
33084001 2020. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
34754175 2021. What will be the role of molnupiravir in the treatment of COVID-19 infection?
34792677 2021. Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.
32955172 2020. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
33498096 2021. Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.
33026699 2020. Being responsible for someone else: a shared duty for parents and heart failure specialists during the COVID-19 pandemic.
34031865 2021. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.
33659979 2021. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
32498078 2020. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
32369103 2020. Sacubitril/valsartan in COVID-19 patients: the need for trials.
32282032 2020. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
32859477 2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
32926917 2020. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.
33011243 2020. New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.
33628162 2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.
34195234 2021. Myocardial Work Efficiency, A Novel Measure of Myocardial Dysfunction, Is Reduced in COVID-19 Patients and Associated With In-Hospital Mortality.
34778271 2021. Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel.
34603042 2021. Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway.
34539406 2021. Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/beta-Catenin Signaling Pathway.
34135764 2021. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-beta1/Smads Pathway.
33519461 2020. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
32564908 2020. COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?
33688410 2020. COVID-19 and Heart Failure: The Big Challenge.
34739696 2021. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
32405088 2020. Cardiological society of India position statement on COVID-19 and heart failure.
33932192 2021. Brief review of the mRNA vaccines COVID-19.
33221168 2021. Potential role of interferons in treating COVID-19 patients.
33083516 2020. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19.
32875060 2020. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.
32724831 2020. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.
33145103 2020. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.
33809971 2021. Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions.
33203141 2020. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
33888248 2021. Another Nudge to Overcome the Treatment-Risk Paradox in Blood Pressure Management.
29042424 2017. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
32597315 2021. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
32694923 2020. Blood Targets of Adjuvant Drugs Against COVID19.
32282502 2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
32301766 2020. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
32937008 2020. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.
33490288 2021. The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus.
34429797 2021. COVID-19 Pneumonia Precipitating Acute Anterior Wall Myocardial Infarction With Large Left Ventricular Apical Thrombus.
33384064 2021. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.
32265149 2020. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.
32493638 2020. Considerations for Heart Failure Care During the COVID-19 Pandemic.
33464336 2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
32558877 2020. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
33342753 2021. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.
33422263 2021. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
33607159 2021. COVID-19, cytokines, inflammation, and spices: How are they related?
32991879 2020. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
32471831 2020. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
32444383 2020. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
33804308 2021. Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value.
33655986 2021. The semantic of a pandemic: Are cardiovascular patients dying "with" or "from" COVID-19? Reflections from a case report.
31567942 2019. Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction.
32587982 2020. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.
33806624 2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.
33837899 2021. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.
32356628 2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
32356627 2020. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
34151392 2021. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
32893306 2020. COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?
32596035 2020. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-kappaB mediated inflammation and glomerulosclerosis in rats.
33275999 2021. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
33687143 2021. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?
33347477 2020. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
33006999 2020. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
33203679 2020. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
33550151 2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
32999856 2020. Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19.
32905015 2020. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
33219294 2020. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
34035891 2021. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis.
32553503 2020. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
34696334 2021. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.
33265982 2020. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.
33877436 2021. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.
33779831 2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.
32719054 2020. Sacubitril, valsartan and SARS-CoV-2.
26057694 2015. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
34075552 2021. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
31790054 2020. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
27653223 2016. Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?
33786624 2021. Sacubitril/valsartan inhibits oxLDLinduced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4/NFkappaB signaling pathway in HUVECs.
